Novartis AG
NVSEF
Rank in Stocks
#54
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stillโs disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Share Price
$160.65
Last synced: 2026-11-10
Market Cap
$303.93B
Change (1 day)
-0.20%
Change (1 year)
26.85%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Novartis AG (NVSEF)
Category
Healthcare
EPS for Novartis AG (NVSEF)
EPS as of September 2026 TTM: $5.19
According to Novartis AG's latest financial reports, its current EPS (TTM) is $5.19. At the end of 2025 the company had an EPS of $7.56, an increase over its 2024 EPS of $5.92.
EPS history for Novartis AG from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $5.19 | -31.35% |
| 2025 | $7.56 | 27.70% |
| 2024 | $5.92 | -22.41% |
| 2023 | $7.63 | 131.91% |
| 2022 | $3.29 | -69.34% |
| 2021 | $10.73 | 185.37% |
| 2020 | $3.76 | 19.37% |
| 2019 | $3.15 | -42.10% |
| 2018 | $5.44 | 65.85% |
| 2017 | $3.28 | 16.31% |
| 2016 | $2.82 | -61.89% |
| 2015 | $7.40 | 75.77% |
| 2014 | $4.21 | 11.97% |
| 2013 | $3.76 | -4.33% |
| 2012 | $3.93 | 4.80% |
| 2011 | $3.75 | -12.38% |
| 2010 | $4.28 | 15.68% |
| 2009 | $3.70 | 2.21% |
| 2008 | $3.62 | -29.71% |
| 2007 | $5.15 | 68.30% |
| 2006 | $3.06 | 16.35% |
| 2005 | $2.63 | 15.35% |
| 2004 | $2.28 | 14.57% |
| 2003 | $1.99 | 5.85% |
| 2002 | $1.88 | 26.17% |
| 2001 | $1.49 | -12.35% |
| 2000 | $1.70 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $30.89 | 495.18% |
US
|
|
| $6.60 | 27.17% |
US
|
|
| $5.83 | 12.33% |
US
|
|
| $18.31 | 252.86% |
CH
|
|
| $0.99 | -80.92% |
US
|
Questions about Novartis AG's earnings per share (EPS)
What is Novartis AG's earnings per share (EPS)?
Novartis AG's earnings per share (EPS) over the last twelve months is $5.19, as of Sep 2026.
What was Novartis AG's earnings per share (EPS) in 2025?
In 2025, Novartis AG's earnings per share (EPS) was $7.56, 27.70% more than in 2024 ($5.92).
How has Novartis AG's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Novartis AG's earnings per share (EPS) went from $3.76 to $7.56, an average growth of 14.99% a year.
How does Novartis AG's earnings per share (EPS) compare with similar companies?
Novartis AG's earnings per share (EPS) ($5.19) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Eli Lilly and Company, with $30.89.